Vanda Pharmaceuticals | VNDA - Equity Capital And Reserves


Vanda Pharmaceuticals reported $327.19M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Akebia Therapeutics USD 25.02M 2.36M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Insmed USD 757.49M 52.64M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Moderna USD 6.76B 647M Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 69.57B 3.24B Jun/2026
Takeda JPY 7.56T 215.7B Jun/2026
Teva Pharmaceutical Industries USD 7.75B 475M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Veracyte USD 1.39B 44M Jun/2026